Immune Response BioPharma and Immune Response Corporation and Orchestra Therapeutics, Inc. Kevin Kimberlin, & Spencer Trask

This blog is concerning a new company recently formed by a David Buswell called Immune Response BioPharma and this companies use of the research begun in 1988 by Kevin Kimberlin and Jonas Salk in a company called the Immune Response Corporation (IMNR) (now Orchestra Therapeutics, Inc.). This company now trades under the symbol OCHTQ.PK. David Buswell and Immune Response BioPharma are now laying claims to the research conducted by Immune Response/Orchestra saying that the research has been abandoned though stockholders in the company still hold, buy and sell stock in the compnay and have not relinquished any of their rights. Immune Response BioPharma plans on issuing stock through an IPO offering though they say that the research they are basing their company on was found in the "trash." This blog is being written by a long time stock holder in IMNR/OCHT who wishes to defend his rights as a stock holder and investor who financed the research that David Buswell and company are now trying to market. I also wish to inform others as to the history and connection of Immune Response BioPharma to Immune Response Corporation and Orchestra Therapeutics, Inc.